Their study demonstrates that inhibiting the EZH2 methyltransferase acts in a synthetic lethal manner in ARID1A-mutated ovarian cancer cells, with ARID1A mutations correlating with the response to the EZH2 inhibitor [207]. This evidence concerns the gene ARID1A and ovarian cancer.